Overview

A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2025-09-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Phase:
Phase 3
Details
Lead Sponsor:
RemeGen Co., Ltd.
Collaborator:
Iqvia Pty Ltd